{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:43:34Z","timestamp":1789753414748,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013041","name":"Vice-Chancellor for Research, Shiraz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Critical Care"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jcrc.2022.154170","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T14:19:03Z","timestamp":1666189143000},"page":"154170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: An assessor-blinded randomized clinical trial"],"prefix":"10.1016","volume":"73","author":[{"given":"Mahtabalsadat","family":"Mirjalili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Zand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Karimzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Masjedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golnar","family":"Sabetian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Vazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jcrc.2022.154170_bb0005","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy313","article-title":"Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit","volume":"5","author":"Sakr","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"10.1016\/j.jcrc.2022.154170_bb0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.mpsur.2015.08.002","article-title":"Sepsis in the intensive care unit","volume":"33","author":"Bennett","year":"2015","journal-title":"Surgery (Oxf)"},{"issue":"11","key":"10.1016\/j.jcrc.2022.154170_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104475","article-title":"Impact of appropriate antimicrobial therapy for patients with severe sepsis and septic shock--a quality improvement study","volume":"9","author":"Yokota","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jcrc.2022.154170_bb0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijantimicag.2013.10.021","article-title":"Prolonging \u03b2-lactam infusion: a review of the rationale and evidence, and guidance for implementation","volume":"43","author":"MacVane","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.jcrc.2022.154170_bb0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jcrc.2022.154170_bb0030","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1128\/CMR.00022-16","article-title":"Continuous and prolonged intravenous \u03b2-lactam dosing: implications for the clinical laboratory","volume":"29","author":"Grupper","year":"2016","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.jcrc.2022.154170_bb0035","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.jcrc.2022.154170_bb0040","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1128\/AAC.02365-12","article-title":"Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections","volume":"57","author":"Bauer","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jcrc.2022.154170_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201667","article-title":"Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis","volume":"13","author":"Yu","year":"2018","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jcrc.2022.154170_bb0050","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1128\/AAC.00329-06","article-title":"Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection","volume":"50","author":"Lau","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.jcrc.2022.154170_bb0055","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1164\/rccm.201505-0857OC","article-title":"A multicenter randomized trial of continuous versus intermittent \u03b2-lactam infusion in severe Sepsis","volume":"192","author":"Dulhunty","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcrc.2022.154170_bb0060","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","article-title":"Continuous versus intermittent \u03b2-lactam infusion in severe Sepsis. A Meta-analysis of individual patient data from randomized trials","volume":"194","author":"Roberts","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcrc.2022.154170_bb0065","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"issue":"5","key":"10.1016\/j.jcrc.2022.154170_bb0070","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ijantimicag.2013.07.012","article-title":"Ampicillin\/sulbactam: its potential use in treating infections in critically ill patients","volume":"42","author":"Adnan","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.jcrc.2022.154170_bb0075","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-0037-1599225","article-title":"Infections due to Acinetobacter baumannii in the ICU: treatment options","volume":"38","author":"Lynch","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.jcrc.2022.154170_bb0080","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1128\/AAC.48.5.1586-1592.2004","article-title":"In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains","volume":"48","author":"Higgins","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jcrc.2022.154170_bb0085","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/00365540600951184","article-title":"High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii","volume":"39","author":"Betrosian","year":"2007","journal-title":"Scand J Infect Dis"},{"issue":"6","key":"10.1016\/j.jcrc.2022.154170_bb0090","first-page":"432","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J Inf Secur"},{"issue":"2","key":"10.1016\/j.jcrc.2022.154170_bb0095","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jcrc.2022.154170_bb0100","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.jcrc.2022.154170_bb0105","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jcrc.2022.154170_bb0110","series-title":"Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI Document M100-S25","author":"CLSI","year":"2015"},{"issue":"9","key":"10.1016\/j.jcrc.2022.154170_bb0115","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/17425250903145251","article-title":"Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections","volume":"5","author":"Betrosian","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.jcrc.2022.154170_bb0120","doi-asserted-by":"crossref","first-page":"294","DOI":"10.30699\/ijmm.12.4.294","article-title":"Antibiotic resistance among Escherichia coli, Pseudomonas aeruginosa and Acinetobacter baumannii isolates obtained from shiraz Nemazi hospital ICU wards","volume":"12","author":"Khashei","year":"2018","journal-title":"Iran J Med Microbiol"},{"issue":"2","key":"10.1016\/j.jcrc.2022.154170_bb0125","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1590\/S1413-86702009000200009","article-title":"Multidrug-resistant bacteria isolated from intensive-care-unit patient samples","volume":"13","author":"Japoni","year":"2009","journal-title":"Braz J Infect Dis: Offl Publ Braz Soc Infect Dis"},{"issue":"3","key":"10.1016\/j.jcrc.2022.154170_bb0130","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jcrc.2022.154170_bb0135","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/IDR.S182585","article-title":"In vitro activity of colistin in combination with various antimicrobials against Acinetobacter baumannii species, a report from South Iran","volume":"12","author":"Kheshti","year":"2019","journal-title":"Infect Drug Resist"},{"issue":"Suppl2","key":"10.1016\/j.jcrc.2022.154170_bb0140","first-page":"206","article-title":"Interim study: comparison of safety and efficacy of levofloxacin plus Colistin regimen with levofloxacin plus high dose ampicillin\/Sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant Acinetobacter","volume":"17","author":"Mosaed","year":"2018","journal-title":"Iran J Pharmaceut Res IJPR"},{"issue":"3","key":"10.1016\/j.jcrc.2022.154170_bb0145","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01268-16","article-title":"High-dose ampicillin-Sulbactam combinations combat Polymyxin-resistant Acinetobacter baumannii in a hollow-Fiber infection model","volume":"61","author":"Lenhard","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.jcrc.2022.154170_bb0150","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","article-title":"Beta-lactam infusion in severe Sepsis (BLISS): a prospective, two-Centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis","volume":"42","author":"Abdul-Aziz","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jcrc.2022.154170_bb0155","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40560-020-00490-z","article-title":"Prolonged versus intermittent \u03b2-lactam antibiotics intravenous infusion strategy in sepsis or septic shock patients: a systematic review with meta-analysis and trial sequential analysis of randomized trials","volume":"8","author":"Kondo","year":"2020","journal-title":"J Intensive Care"},{"issue":"1","key":"10.1016\/j.jcrc.2022.154170_bb0160","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40560-020-00490-z","article-title":"Prolonged versus intermittent \u03b2-lactam antibiotics intravenous infusion strategy in sepsis or septic shock patients: a systematic review with meta-analysis and trial sequential analysis of randomized trials","volume":"8","author":"Kondo","year":"2020","journal-title":"J Intensive Care"},{"issue":"1","key":"10.1016\/j.jcrc.2022.154170_bb0165","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jcrc.2022.154170_bb0170","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1177\/0300060518822404","article-title":"Prognostic significance of PCT and CRP evaluation for adult ICU patients with sepsis and septic shock: retrospective analysis of 59 cases","volume":"47","author":"Cui","year":"2019","journal-title":"J Int Med Res"},{"issue":"5","key":"10.1016\/j.jcrc.2022.154170_bb0175","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/phar.2112","article-title":"Procalcitonin monitoring as a guide for antimicrobial therapy: a review of current literature","volume":"38","author":"Covington","year":"2018","journal-title":"Pharmacotherapy."},{"issue":"2","key":"10.1016\/j.jcrc.2022.154170_bb0180","first-page":"59","article-title":"Clinical utility and measurement of Procalcitonin","volume":"38","author":"Samsudin","year":"2017","journal-title":"Clin Biochem Rev"},{"issue":"2","key":"10.1016\/j.jcrc.2022.154170_bb0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4037\/ccn2014559","article-title":"Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections","volume":"34","author":"Stannard","year":"2014","journal-title":"Crit Care Nurse"},{"key":"10.1016\/j.jcrc.2022.154170_bb0190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40560-017-0246-8","article-title":"Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy","volume":"5","author":"Vijayan","year":"2017","journal-title":"J Intensive Care"},{"key":"10.1016\/j.jcrc.2022.154170_bb0195","first-page":"278","article-title":"Using Procalcitonin to Guide Antibiotic Escalation in Patients With Suspected Bacterial Infection: A New Application of Procalcitonin in the Intensive Care Unit","author":"Wang","year":"2022","journal-title":"Frontiers in cellular and infection microbiology."},{"issue":"7","key":"10.1016\/j.jcrc.2022.154170_bb0200","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","article-title":"Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial","volume":"16","author":"de Jong","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jcrc.2022.154170_bb0205","first-page":"338","article-title":"Stability of ampicillin in Normal saline and buffered Normal saline","volume":"20","author":"Maher","year":"2016","journal-title":"Int J Pharmaceut Compounding"},{"issue":"6","key":"10.1016\/j.jcrc.2022.154170_bb0210","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ijantimicag.2005.02.008","article-title":"Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics","volume":"25","author":"Munckhof","year":"2005","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.jcrc.2022.154170_bb0215","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/43.4.523","article-title":"Continuous infusion versus intermittent administration of meropenem in critically ill patients","volume":"43","author":"Thalhammer","year":"1999","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.jcrc.2022.154170_bb0220","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.clinthera.2012.11.005","article-title":"Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients","volume":"34","author":"Lee","year":"2012","journal-title":"Clin Ther"}],"container-title":["Journal of Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088394412200199X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088394412200199X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:49:17Z","timestamp":1760125757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088394412200199X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":44,"alternative-id":["S088394412200199X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcrc.2022.154170","relation":{},"ISSN":["0883-9441"],"issn-type":[{"value":"0883-9441","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: An assessor-blinded randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Critical Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrc.2022.154170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154170"}}